Pharmacokinetic of ropivacaine in combined lumbosacral plexus and T12, L1 paravertebral nerve block in the elderly

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044832

Enrollment

Unknown

Registered

2021-03-29

Start date

2018-09-01

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacokinetic of ropivacaine in the elderly

Interventions

experimental group:combined lumbosacral plexus and T12,L1 paravertebral nerve block

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients planning to undergo hip replacement surgery; 2. Weight >= 50kg, aged >= 65 years; 3. ASA grade I to IV.

Exclusion criteria

Exclusion criteria: 1. Patients allergy to amide drugs or with peripheral neuropathy, skin infections at or near the puncture site, coagulation dysfunction, liver and kidney dysfunction; 2. Patients using fluvoxamine, ciprofloxacin, ketoconazole, erythromycin, clarithromycin, Itraconazole or rifampin (such drugs can affect the clearance of ropivacaine).

Design outcomes

Primary

Measure	Time frame
Arterial blood ropivacaine concentration;	—

Countries

China

Contacts

Public ContactChu Qinjun

Zhengzhou Central Hospital Affiliated to Zhengzhou University

jimmynetchu@163.com+86 13838100696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026